INTRODUCTION

The outbreak of Coronavirus disease (COVID-19), which was first reported in early December 2019 in Wuhan, China has emerged as one of the most serious global pandemic and global health hazard (Huang, Wang, et al., 2020). The cases of COVID-19 are still rapidly increasing with higher morbidity and mortality. Globally, there have been 146,067,511 confirmed COVID-19 patients by 25 April 2021 and among them 3,092,497 lost their lives (World Health Organization, 2021). The clinical manifestations highly range from asymptomatic to symptomatic and shows clusters of flu like symptoms such as fever, fatigue, myalgia, dry cough, dyspnoea, anorexia and so on (Hong et al., 2020; Huang, Wang, et al., 2020; Huang, Lian, et al., 2020). Patients are classified into four type, that is, mild, moderate, severe and critical based on clinical manifestation and laboratory findings. Some studies have documented that...
COVID-19-infected patients who already have pre-existing comorbidities such as hypertension, diabetes, congestive heart failure, cardiovascular diseases, cerebrovascular disease, chronic kidney disease (CKD), chronic liver disease, cancer, chronic obstructive pulmonary disease and asthma leads to poor prognosis or even fatal outcomes (Giri et al., 2020; Gregoriano et al., 2020; Yang, Zheng, et al., 2020; Zhou, Yang, et al., 2020). In addition, the older people who already have above listed underlying chronic conditions are more susceptible to COVID-19. Severe cases admitted in intensive care unit with pre-existing comorbidities yield poorer clinical outcomes than those without (Abraham et al., 2020; Guan et al., 2020; Huang, Wang, et al., 2020; Tabata et al., 2020).

Thus, it is critical to thoroughly understand and identify the actual high-risk comorbidities, which are closely associated with COVID-19 in order to do prompt management and prevent the deterioration from mild and moderate conditions to the severe ones. Thus far, most of published meta-analysis about the comorbidity in severe COVID-19 patients included limited studies and most studies included in these meta-analysis were conducted in China. Therefore, it is necessary to carry out a meta-analysis to give systematic evaluation of common comorbidities in severe and non-severe COVID-19 patients around the globe. To the best of our knowledge, this is the first study to compare comorbidities among severe and non-severe COVID-19 patients in Asian versus non-Asian populations.

2 | METHODS

2.1 | Eligibility criteria

For research article selection the inclusion criteria were as follows: (1) Study population: Studies with patients diagnosed with COVID-19; (2) Comparative studies: Studies that compared severe or ICU (elevated troponin T (TnT) level as the second choice if severe or ICU data were not given) and non-sever or non-ICU (normal TnT level as the second choice if severe or ICU (elevated troponin T (TnT) level as the second choice if severe or ICU data were not given) cases of COVID-19; and (3) The studies reporting parameters of comorbidities such as hypertension, diabetes, cardiovascular disease, cancer, chronic obstructive pulmonary disease and chronic kidney disease. Non-English studies, letters, case studies, editorials, conference abstract, vaccination trials studies and articles with only abstract were excluded. Studies with fewer than 20 cases were also excluded.

2.2 | Information sources and Searching strategies

This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement guidelines (Moher et al., 2009). PRISMA checklist was followed step by step (Electronic Supplementary information Appendix S1). We used PubMed, Embase, Scopus and Web of Science online database to conduct a comprehensive search up to 24 March 2021, with following search terms: “COVID-19,” “Novel coronavirus,” “SARS-CoV-2,” “Coronavirus disease-19,” “Epidemiological character,” “Clinical features,” “Clinical character,” “Clinical Presentation,” “comorbidities,” “Comorbidities” and “Complications.” Full electronic search strategy in PubMed database can be found here (Electronic Supplementary information Appendix S2). We applied search filters to include English language studies. We screened reference lists of included studies to ensure literature saturation.

2.3 | Data extraction

Microsoft Excel database was used to record all available information. Two authors (AP and LH) who performed the literature search also independently extracted following items from each article: first author, publication year, country, study design, age, gender, sample size and number of people in severe and non-severe group. In case of missing data, we also contacted the authors of an article to obtain more precise data about the comorbidities of the patients evaluated. Disagreement occurred during research period were resolved by consensus with third author. The primary outcome measure was to compare the proportion of comorbidities such as hypertension, diabetes, cardiovascular disease, and chronic kidney disease in severe group versus non-severe group for both Asian and non-Asian studies.

2.4 | Risk of bias assessment

Methodological index for non-randomized studies (MINORS) (Slim et al., 2003) was used to assess methodological quality of included studies by two independent researchers. Each item in the MINORS has three scores: 0, unreported; 1, reported but inadequately or partially; and 2, adequately reported. The total score is 24. The detailed risk of bias for all the included studies using MINORS criteria score is presented in Table 1. According to MINORS criteria score the studies were classified as very low quality (0–6), low quality (7–12), moderate quality (13–18) and high quality (19–24). Two reviewers independently assessed the quality of included studies and disagreements were resolved through discussion with third reviewer. Publication bias among included studies was assessed by funnel plots and a symmetrical plot indicated low-risk publication bias.

2.5 | Statistical analysis

Meta-analysis was performed using RevMan software version 5.3. We calculated pooled odds ratio (OR) and 95% CI for comorbidities, in severe versus non-severe Asian and non-Asian studies. Heterogeneity between studies was assessed using the Cochran Q test and $I^2$ statistics. Generally, in cases of $I^2$ being larger than 50%, a random-effect model is used, otherwise a fixed-effect model is used. However, owing to the clinical heterogeneity inherent in
TABLE 1 MINORS rating scale for quality of included studies

| Study          | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Score |
|----------------|---|---|---|---|---|---|---|---|---|----|----|----|-------|
| Asian studies  |   |   |   |   |   |   |   |   |   |    |    |    |       |
| Abohamr SI     | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Alqahtani AM   | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 19    |
| Bastug A       | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20    |
| Cao J          | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 19    |
| Cao Z          | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Du RH          | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20    |
| Guan WJ        | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Güner R        | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Guo T          | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Hong KS        | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Huang C        | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 21    |
| Huang R        | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Khamis F       | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20    |
| Khan A         | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Lee JY         | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Lee SG         | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Li C           | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Li K           | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 19    |
| Li X           | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Lv Z           | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20    |
| Omrani A       | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Shabrawish M   | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Shahriarirad R | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Shi S          | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 21    |
| Tabata S       | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Tian S         | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Wan S          | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Wang D         | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 21    |
| Wang W         | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20    |
| Wang Y         | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 19    |
| Wang Z         | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 21    |
| Wei Y          | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Wu J           | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Xiong F        | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Xiong S        | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Yang L         | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Zhang G        | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Zhang JJ       | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Zhou J         | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Non-Asian studies | |   |   |   |   |   |   |   |   |    |    |    |       |
| Argenziano MG  | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 21    |
| Buckner FS     | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Cattelan AM    | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Ferguson J     | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |

(Continues)
the data and the different effect sizes of included studies we used random-effects analysis for all meta-analyses. The $I^2$ values of $<25\%$, $25\%$–$50\%$, $50\%$–$75\%$ and $75\%$–$100\%$ were regarded as homogeneous, low, moderate and high heterogeneous levels, respectively. The $p$-value less than 0.05 was used to indicate statistical significance.

### 3.1 Study characteristics and quality

A total of 66 studies were included among them 39 studies were Asian and 27 were non-Asian. Out of 39 Asian studies, most of them were carried out in China ($N = 26$) (Cao, Li, et al., 2020; Cao, Zheng, et al., 2020; Du et al., 2020; Guan et al., 2020; Guo et al., 2020; Huang, Wang, et al., 2020; Huang, Zhu, et al., 2020; Li, Jiang, et al., 2020; Li, Wu, et al., 2020; Li, Xu, et al., 2020; Lu et al., 2020; Shi et al., 2020; Tian et al., 2020; Wan et al., 2020; Wang, Hu, et al., 2020; Wang, Xin, et al., 2020; Wang, Yang, et al., 2020; Wang, Zhen, et al., 2020; Wei et al., 2020; Wu et al., 2020; Xiong, Liu, et al., 2020; Xiong, Tang, et al., 2020; Yang, Liu, et al., 2020; Zhang, Dong, et al., 2020; Zhang, Hu, et al., 2020; Zhou, Sun, et al., 2020), followed by Saudi Arabia ($N = 4$) (Abohamr et al., 2020; Alqahtani et al., 2020; Khan et al., 2020; Shabrawishi et al., 2020), South Korea ($N = 3$) (Hong et al., 2020; Lee, Hong, et al., 2020; Lee, Park, et al., 2020), Turkey ($N = 2$) (Bastug et al., 2020; Güner et al., 2020), Oman ($N = 1$) (Khamis et al., 2020), Qatar ($N = 1$) (Omran et al., 2020), Iran ($N = 1$) (ShahriariRad et al., 2020), and Japan ($N = 1$) (Tabata et al., 2020). Most of the non-Asian studies

| Study          | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Score |
|---------------|---|---|---|---|---|---|---|---|---|----|----|----|-------|
| Filardo TD    | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Garibaldi BT  | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Giustino G    | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Gregoriano C  | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 19    |
| Israelsen SB  | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Jourdes A     | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Kaeuffer C    | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Lombardi CM   | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Matangiya JR  | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20    |
| Ortiz-Brizuela| 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Oul D         | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Pellaud C     | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |
| Petrilli CM   | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Popov GT      | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Raad M        | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Reilev M      | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Samuels S     | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20    |
| Schönfeld D   | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 19    |
| Stefan, G.    | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Sulejmani A   | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18    |
| Suleyman G    | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Turcotte JJ   | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19    |
| Yazdanpanah Y | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20    |

Note: ① A clearly stated aim; ② Inclusion of consecutive patients; ③ Prospective collection of data; ④ Endpoints appropriate to the aim of the study; ⑤ Unbiased assessment of the study endpoint; ⑥ Follow-up period appropriate to the aim of the study; ⑦ Loss to follow up less than 5%; ⑧ Prospective calculation of the study size; ⑨ Appropriate selection of control group; ⑩ Synchronization of control group; ⑪ Baseline comparable between groups; ⑫ Appropriately statistical analysis. The global ideal score being 24 for comparative studies.
were conducted in United States (N = 12) (Argenziano et al., 2020; Buckner et al., 2020; Ferguson et al., 2020; Filardo et al., 2020; Garibaldi et al., 2021; Giustino et al., 2020; Oud & Garza, 2021; Petrilli et al., 2020; Raad et al., 2020; Samuels et al., 2021; Suleyman et al., 2020; Turcotte et al., 2020), followed by Italy (N = 3) (Cattelan et al., 2020; Lombardi et al., 2020; Sulejmani et al., 2021), France (N = 3) (Jourdes et al., 2020; Kaeuffer et al., 2020; Yazdanpanah, 2021), Switzerland (N = 2) (Gregoriano et al., 2020; Pellaud et al., 2020), Denmark (N = 2) (Israelsen et al., 2020; Reilev et al., 2020), Congo (N = 1) (Matangila et al., 2020), Mexico (N = 1) (Ortiz-Brizuela et al., 2020), Bulgaria (N = 1) (Popov et al., 2020), Argentina (N = 1) (Schönfeld et al., 2021) and Romania (N = 1) (Stefan et al., 2021). All included studies were published in 2020 and 2021 with varying sample size that ranged from 37 to 207,079 patients. The characteristics of the included studies are depicted in Table 2. We performed assessments of risk of bias for all the included studies using MINORS rating scale and reported in Table 1. The mean MINORS score was 19.23 ± 0.91 (range: 18–21) out of a possible 24 for comparative studies (Table 1). All of the included studies were moderate-to-high quality.

### 3.2 Hypertension in Asian and non-Asian population

Fifty eight studies reported data on hypertension in severe and non-severe COVID-19 patients. The overall pooled incidence of
| Study                        | Type of study design | Country       | Total patients | Age, years<sup>a</sup> | Male | Non-sever patients | Age, years<sup>a</sup> | Male |
|-----------------------------|----------------------|---------------|----------------|------------------------|------|-------------------|------------------------|------|
| **Asian studies**           |                      |               |                |                        |      |                   |                        |      |
| Abohamr SI                  | Retrospective        | Saudi Arabia | 768            | 47.4 ± 13.8           | 284  | 45.5 ± 13.5       | 305                    |      |
| Alqahtani AM                | Retrospective        | Saudi Arabia | 458            | NA                     | 37   | NA                | 361                    |      |
| Bastug A                    | Retrospective        | Turkey        | 191            | 71 (28–91)            | 26   | 43 (18–83)        | 81                     |      |
| Cao J                       | Retrospective        | China         | 244            | 62.20 ± 13.43         | 63   | 59.79 ± 13.49     | 44                     |      |
| Cao Z                       | Retrospective        | China         | 80             | 71 ± 15               | 16   | 44 ± 16           | 22                     |      |
| Du RH                       | Retrospective        | China         | 109            | 68.4 ± 9.7            | 36   | 72.7 ± 11.6       | 38                     |      |
| Guo T                       | Retrospective        | China         | 187            | 71.4 ± 9.43           | 34   | 53.53 ± 13.22     | 57                     |      |
| Hong KS                     | Retrospective        | South Korea  | 98             | 63.2 ± 10.1           | 6    | 54.2 ± 17.7       | 32                     |      |
| Huang C                     | Prospective          | China         | 41             | 49 (41–61)            | 11   | 49 (41–57.5)      | 19                     |      |
| Huang R                     | Retrospective        | China         | 202            | 49 (35–59)            | 17   | 44 (33–53)        | 99                     |      |
| Khamis F                    | Retrospective        | Oman          | 63             | 50 ± 17               | 21   | 47 ± 16           | 32                     |      |
| Khan A                      | Retrospective        | Saudi Arabia | 648            | 37 (27)               | 52   | 33 (18)           | 290                    |      |
| Lee JY                      | Retrospective        | South Korea  | 694            | NA                    | 57   | NA                | 155                    |      |
| Lee SG                      | Retrospective        | South Korea  | 7339           | 66.8 ± 15.2           | 441  | 44.2 ± 17.8       | 2529                   |      |
| Li C                        | Retrospective        | China         | 2068           | 69 (60–78)            | 282  | 61 (49–68)        | 723                    |      |
| Li K                        | Retrospective        | China         | 83             | 53.7 ± 12.3           | 15   | 41.9 ± 10.6       | 29                     |      |
| Li X                        | Retrospective        | China         | 548            | 65 (54–72)            | 153  | 56 (44–66)        | 126                    |      |
| Lv Z                        | Retrospective        | China         | 354            | 62 (25–89)            | 77   | 61 (23–79)        | 58                     |      |
| Omrani AS                   | Retrospective        | Qatar         | 5000           | 49.5 (39.5–60)        | 100  | 38 (30–49)        | 1067                   |      |
| Shabrawishi M               | Retrospective        | Saudi Arabia | 150            | 49.8 ± 15.7           | 13   | 45.4 ± 16         | 58                     |      |
| Shahriarirad R              | Retrospective        | Iran          | 113            | NA                    | 7    | NA                | 64                     |      |
| Shi S                       | Cohort               | China         | 416            | 74 (34–95)            | 44   | 60 (21–90)        | 161                    |      |
| Tabata S                    | Retrospective        | Japan         | 104            | 73 (55–77)            | 17   | 60 (40–71)        | 22                     |      |
| Tian S                      | Retrospective        | China         | 262            | 61.4 (1–94)           | 26   | 44.5 (1–93)       | 101                    |      |
| Wan S                       | Retrospective        | China         | 135            | 56 (52–73)            | 21   | 44 (33–49)        | 52                     |      |
| Wang D                      | Retrospective        | China         | 138            | 66 (57–78)            | 22   | 51 (37–62)        | 53                     |      |
| Wang W                      | Retrospective        | China         | 421            | 56 (45–63)            | 28   | 51 (38–60)        | 186                    |      |
| Wang Y                      | Retrospective        | China         | 222            | 70 (65.5–80)          | 12   | 60.5 (48–67)      | 96                     |      |
| Wang Z                      | Retrospective        | China         | 69             | 70.5 (62–77)          | 7    | 37 (32–51)        | 25                     |      |
| Wei Y                       | Retrospective        | China         | 276            | 65 (60–72.8)          | 10   | 50 (39–57)        | 145                    |      |
| Wu J                        | Retrospective        | China         | 280            | 63.04 ± 10.20         | 45   | 37.55 ± 17.10     | 106                    |      |
| Xiong F                     | Retrospective        | China         | 131            | 63.3 ± 12.4           | 17   | 63.1 ± 13.4       | 58                     |      |
| Xiong S                     | Retrospective        | China         | 116            | 64 (53–76)            | 38   | 56 (37–64)        | 42                     |      |
| Yang L                      | Retrospective        | China         | 200            | 71 ± 13.4             | 16   | 52 ± 16.2         | 82                     |      |
| Zhang G                     | Retrospective        | China         | 221            | 62 (52–74)            | 35   | 51 (36–64.3)      | 73                     |      |
| Zhang JJ                    | Retrospective        | China         | 140            | 64 (25–87)            | 33   | 51.5 (26–78)      | 38                     |      |
| Zhou J                      | Retrospective        | China         | 201            | 57 (46–66)            | 27   | 40 (31–53)        | 75                     |      |
| **Non-Asian studies**       |                      |               |                |                        |      |                   |                        |      |
| Argenziano MG               | Retrospective        | USA           | 1000           | 62 (52–72)            | 158  | 64 (51–77)        | 353                    |      |
| Buckner FS                  | Retrospective        | USA           | 105            | 70 (23–97)            | 30   | 67 (25–96)        | 23                     |      |
| Cattelan AM                 | Retrospective        | Italy         | 303            | 68 (56–77)            | 53   | 60 (47–72)        | 129                    |      |

(Continues)
hypothesis was significantly higher in severe patients (50.90%) compared to non-severe patients (30.71%). In subgroup analysis, the proportion of hypertension was significantly higher in severe group than in non-severe group for Asian studies (OR = 2.46, 95% CI: 1.94–3.11; \( p < .00001 \)) (Table 3 and Figure 2). There was high heterogeneity among the included studies (\( I^2 = 82\% \)). Similarly, non-Asian studies also showed statistically significant difference in hypertension incidence in severe and non-severe patients (OR = 1.60, 95% CI: 1.37–1.86, \( I^2 = 84\% \); \( p < .00001 \)) (Table 3 and Figure 2).

### 3.3 Diabetes in Asian and non-Asian population

Data on the diabetes were reported in the 62 studies. The overall pooled estimate showed significantly higher incidence of diabetes in severe patients than non-severe patients (OR = 1.95, 95% CI: 1.71–2.22, \( I^2 = 83\% \); \( p < .001 \)) (Table 3 and Figure 3). In Asian studies, the proportion of diabetes was statistically significant higher in severe patients compared with non-severe patients (OR = 2.70, 95% CI: 2.16–3.37, \( I^2 = 71\% \); \( p < .00001 \)). In non-Asian studies, the pooled odds of diabetes was also significantly higher in patients with severe disease than in those without (OR = 1.44, 95% CI: 1.27–1.63, \( I^2 = 75\% \); \( p < .00001 \)) (Table 3 and Figure 3).

### 3.4 Cardiovascular disease in Asian and non-Asian population

Pooled findings of 48 studies revealed significantly higher incidence of cardiovascular disease in severe patients compared to non-severe patients (OR = 2.47, 95% CI: 2.00–3.06, \( I^2 = 79\% \); \( p < .00001 \)) (Table 3 and Figure 4). The subgroup analysis of both Asian (OR = 3.72, 95% CI: 2.87–4.81, \( I^2 = 62\% \); \( p < .00001 \)) and non-Asian (OR = 1.52, 95% CI: 1.20–1.92, \( I^2 = 71\% \); \( p = .0005 \)) (Table 3 and Figure 4) studies demonstrated statistically significant differences in cardiovascular disease incidence between severe and non-severe patients.

### 3.5 Cancer in Asian and non-Asian population

Data on cancer were reported by forty seven studies and pooled analysis revealed significantly higher incidence of cancer in severe patients than non-severe patients (OR = 2.90, 95% CI: 2.52–3.31; \( p < .00001 \)) (Table 3 and Figure 5).
patients than non-severe patients (OR = 1.63, 95% CI: 1.29–2.06, \( I^2 = 82\% \); \( p < .0001 \)) (Table 3 and Figure 5). Furthermore, Asian studies showed statistically significant difference in cancer incidence between severe and non-severe patients (OR = 2.31, 95% CI: 1.68–3.18, \( I^2 = 29\% \); \( p < .00001 \)), while no statistically significant differences in cancer incidence were noted for non-Asian patients with COVID-19 (OR = 1.26, 95% CI: 0.96–1.64, \( I^2 = 87\% \); \( p = .10 \)) (Table 3 and Figure 5) in subgroup analysis.

### 3.7 Chronic kidney disease in Asian and non-Asian population

In terms of chronic kidney disease, thirty eight studies reported data in severe and non-severe COVID-19 patients. Compared with non-severe, severe patients revealed significantly higher incidence of chronic kidney disease in pooled analysis (OR = 2.23, 95% CI: 1.77–2.8, \( I^2 = 86\% \); \( p < .00001 \)) (Table 3 and Figure 7). Additionally, there was statistically significant differences in both Asian (OR = 3.24, 95% CI: 2.01–5.23, \( I^2 = 66\% \); \( p = .03 \)) and non-Asian (OR = 1.79, 95% CI: 1.39–2.30, \( I^2 = 90\% \); \( p < .00001 \)) studies in terms of chronic kidney disease severity in subgroup analysis.

### 3.8 Publication bias

Funnel plots for all six comorbidities are included in supplementary information (Figures S1–S6). Nearly symmetrical graphical funnel
### Figure 2

Forest plot for the ORs for comparing hypertension between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients.

| Study or Subgroup | Severe Events | Non-severe Events | Odds Ratio | Weight |
|-------------------|--------------|-------------------|------------|--------|
| Abrahmiri SI      | 141          | 352               | 1.56       | 2.6%   |
| Alqahtani AM      | 36           | 47                | 92.81      | 1.4%   |
| Bastug A          | 15           | 46                | 5.36       | 1.4%   |
| Cao J             | 41           | 107               | 2.07       | 1.8%   |
| Cao Z             | 4            | 27                | 0.40       | 1.3%   |
| Du RH             | 29           | 51                | 0.81       | 1.6%   |
| Guan WJ           | 41           | 173               | 2.01       | 2.3%   |
| Gumer N           | 16           | 50                | 1.78       | 1.7%   |
| Guo T             | 33           | 52                | 6.64       | 1.3%   |
| Hong KS           | 5            | 13                | 1.50       | 0.9%   |
| Huang C           | 2            | 13                | 1.09       | 0.5%   |
| Huang R           | 2            | 23                | 0.54       | 0.7%   |
| Khamis F          | 7            | 24                | 0.82       | 1.0%   |
| Khan A            | 16           | 77                | 2.28       | 1.9%   |
| Lee JY            | 45           | 137               | 2.68       | 2.3%   |
| Lee SG            | 371          | 927               | 3.60       | 2.8%   |
| Li C              | 233          | 476               | 2.16       | 2.7%   |
| Li K              | 2            | 25                | 1.59       | 0.6%   |
| Li X              | 104          | 269               | 2.21       | 2.4%   |
| Lv X              | 33           | 165               | 1.08       | 1.9%   |
| Omrani AS         | 52           | 108               | 3.94       | 2.3%   |
| Shobrakhshi M     | 3            | 16                | 0.60       | 0.8%   |
| Shahriari R       | 5            | 11                | 4.17       | 1.2%   |
| Shi S             | 49           | 82                | 4.87       | 2.1%   |
| Wang D            | 21           | 36                | 5.09       | 1.5%   |
| Wang W            | 8            | 59                | 1.42       | 1.5%   |
| Wang Y            | 11           | 29                | 2.48       | 1.4%   |
| Wang Z            | 5            | 14                | 7.08       | 0.7%   |
| Wei Y             | 8            | 14                | 7.62       | 1.0%   |
| Xiong S           | 26           | 55                | 1.98       | 1.6%   |
| Yang L            | 9            | 29                | 1.69       | 1.4%   |
| Zhang G           | 26           | 55                | 4.42       | 1.8%   |
| Zhang JJ          | 22           | 58                | 1.89       | 1.6%   |
| Subtotal (95% CI) | 3650         | 15707             | 2.46       | 52.4%  |

Total events: 1425
Heterogeneity: Tau² = 0.32; Chi² = 181.46; df = 33 (P < 0.00001); I² = 82%
Test for overall effect: Z = 7.50 (P < 0.00001)

### Non-Asian studies

| Study or Subgroup | Severe Events | Non-severe Events | Odds Ratio | Weight |
|-------------------|--------------|-------------------|------------|--------|
| Argenziano MG     | 158          | 236               | 1.38       | 2.5%   |
| Buckner FS        | 30           | 51                | 0.98       | 1.5%   |
| Cattelan AM       | 50           | 69                | 3.35       | 1.9%   |
| Garabaldi BT      | 71           | 171               | 0.91       | 2.5%   |
| Giustino G        | 130          | 190               | 2.72       | 2.2%   |
| Gregoriano C      | 19           | 35                | 0.87       | 1.4%   |
| Israelsson SB     | 11           | 27                | 0.95       | 1.4%   |
| Joung JH          | 19           | 50                | 0.92       | 1.3%   |
| Kaufer C          | 231          | 432               | 1.15       | 2.7%   |
| Lombardi CM       | 182          | 278               | 1.90       | 2.5%   |
| Malangila JR      | 21           | 49                | 2.13       | 1.6%   |
| Ortiz-Erriqueza E | 10           | 29                | 1.14       | 1.4%   |
| Pellaud C         | 27           | 49                | 0.76       | 1.8%   |
| Petilli CM         | 680          | 990               | 1.57       | 2.8%   |
| Popov GT          | 32           | 43                | 4.56       | 1.5%   |
| Raad M            | 333          | 390               | 3.16       | 2.5%   |
| Reillev M         | 177          | 314               | 1.09       | 2.7%   |
| Samuels S         | 109          | 147               | 1.86       | 2.3%   |
| Schöpfeld D       | 2763         | 5652              | 1.87       | 2.9%   |
| Stefan G          | 13           | 15                | 1.91       | 0.5%   |
| Suljeman A        | 77           | 136               | 1.71       | 1.6%   |
| Suleymen G        | 111          | 147               | 1.69       | 2.1%   |
| Turtocchi JJ      | 35           | 48                | 1.73       | 1.9%   |
| Yazdanpanah Y     | 31           | 70                | 2.48       | 1.3%   |
| Subtotal (95% CI) | 9604         | 56260             | 1.60       | 47.6%  |

Total events: 5320
Heterogeneity: Tau² = 0.08; Chi² = 94.99; df = 23 (P < 0.00001); I² = 76%
Test for overall effect: Z = 5.97 (P < 0.00001)

### Analysis

- **Study or Subgroup** lists the names of the studies.
- **Severe Events** and **Non-severe Events** indicate the number of severe and non-severe cases, respectively.
- **Odds Ratio** shows the odds ratio for comparing hypertension between severe and non-severe cases.
- **Weight** indicates the weight of each study in the meta-analysis.

**Analysis of Asian studies**:
- **Total** events: 1425
- **Heterogeneity**: Tau² = 0.32; Chi² = 181.46; df = 33 (P < 0.00001); I² = 82%
- **Test for overall effect**: Z = 7.50 (P < 0.00001)

**Analysis of Non-Asian studies**:
- **Total** events: 5320
- **Heterogeneity**: Tau² = 0.08; Chi² = 94.99; df = 23 (P < 0.00001); I² = 76%
- **Test for overall effect**: Z = 5.97 (P < 0.00001)
FIGURE 3 Forest plots depict the comparison of diabetes between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients.
FIGURE 4  Forest plot for the ORs for comparing cardiovascular disease between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients.
FIGURE 5 Forest plots depict the ORs for comparing cancer between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients.
plots were obtained from all included studies evaluating comorbidities between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients. This visual symmetry and funnel shape suggested a low risk of publication bias.

### 2.5.1 Asian studies

| Study or Subgroup | Severe Events | Non-severe Events | Total Events | Total Weight | Odds Ratio M-H, Random, 95% CI |
|-------------------|---------------|-------------------|-------------|-------------|-------------------------------|
| Cao Z             | 0             | 27                | 5           | 53          | 0.16 [0.01, 3.01]             |
| Guan WJ           | 6             | 173               | 6           | 926         | 5.51 [1.76, 17.29]           |
| Guner R           | 6             | 50                | 6           | 172         | 2.86 [1.30, 5.91]           |
| Guo T             | 4             | 52                | 0           | 135         | 0.63 [0.18, 2.22]           |
| Huang C           | 1             | 13                | 0           | 28          | 0.68 [0.26, 1.79]           |
| Lee JY            | 2             | 137               | 2           | 557         | 4.11 [0.57, 29.45]          |
| Lee SG            | 32            | 927               | 49          | 6412        | 4.64 [2.96, 7.29]           |
| Li C              | 16            | 476               | 16          | 1592        | 3.43 [1.70, 6.90]           |
| Li K              | 4             | 25                | 1           | 58          | 10.86 [1.15, 102.77]        |
| Li X              | 13            | 269               | 4           | 279         | 3.49 [1.12, 10.85]          |
| Lv Z              | 3             | 155               | 2           | 115         | 1.12 [0.18, 6.78]           |
| Shabrawishi M     | 1             | 16                | 0           | 105         | 20.42 [0.80, 523.84]        |
| Shahraniad R      | 1             | 11                | 8           | 102         | 1.18 [0.13, 10.38]          |
| Shi S             | 6             | 82                | 6           | 334         | 4.32 [1.35, 13.75]          |
| Won S             | 4             | 40                | 0           | 95          | 23.55 [1.24, 440.35]        |
| Wang D            | 3             | 36                | 1           | 102         | 9.16 [0.92, 91.31]          |
| Wang W            | 1             | 59                | 17          | 362         | 0.35 [0.05, 2.68]           |
| Wang Z            | 2             | 14                | 2           | 55          | 4.42 [0.56, 34.57]          |
| Wei Y             | 2             | 14                | 5           | 262         | 8.57 [1.51, 46.76]          |
| Wu J              | 1             | 83                | 0           | 197         | 7.18 [0.29, 178.12]         |
| Xiong F           | 1             | 30                | 4           | 101         | 0.84 [0.09, 7.78]           |
| Xiong S           | 1             | 55                | 0           | 61          | 3.39 [0.14, 84.84]          |
| Zhang G           | 4             | 55                | 2           | 166         | 6.43 [1.14, 36.14]          |
| Zhang JJ          | 2             | 58                | 0           | 82          | 7.30 [0.34, 154.96]         |
| Subtotal (95% CI) |               |                   |             | 2857        | 4.04 [3.05, 5.34]           |

Total events: 116, Heterogeneity: Tau^2=0.01; Chi^2=23.22, df=23 (P=0.45); I^2=1%

Total events: 136, Heterogeneity: Tau^2=0.32; Chi^2=23.22, df=23 (P=0.45); I^2=1%

Test for overall effect: Z=9.76 (P<0.00001)

### 2.5.2 Non-Asian studies

| Study or Subgroup | Severe Events | Non-severe Events | Total Events | Total Weight | Odds Ratio M-H, Random, 95% CI |
|-------------------|---------------|-------------------|-------------|-------------|-------------------------------|
| Argenziano MG     | 14            | 236               | 42          | 614         | 0.86 [0.46, 1.60]           |
| Buckner FS        | 7             | 51                | 4           | 54          | 2.55 [1.55, 7.25]           |
| Garibaldi BT      | 28            | 171               | 95          | 523         | 0.88 [0.56, 1.40]           |
| Giustino G        | 10            | 190               | 8           | 115         | 0.74 [0.28, 1.94]           |
| Gregoriano C      | 4             | 35                | 4           | 64          | 2.11 [0.45, 8.72]           |
| Israelens SB      | 2             | 27                | 9           | 148         | 1.24 [0.25, 6.06]           |
| Lombardi CM       | 31            | 278               | 27          | 336         | 1.44 [0.84, 2.47]           |
| Ortiz-Brizuela E  | 1             | 29                | 1           | 111         | 3.93 [0.24, 64.78]          |
| Perioli C         | 5             | 49                | 11          | 147         | 1.40 [0.46, 4.27]           |
| Petrioli CM       | 169           | 990               | 284         | 1739        | 1.05 [0.86, 1.30]           |
| Popov GT          | 3             | 43                | 1           | 95          | 7.05 [0.71, 69.84]          |
| Raad M            | 50            | 390               | 55          | 630         | 1.54 [1.02, 2.31]           |
| Schonfeld D       | 548           | 5652              | 2296        | 41703       | 1.84 [1.67, 2.03]           |
| Stefan G          | 3             | 15                | 0           | 22          | 12.60 [0.60, 264.14]        |
| Suleyman G        | 18            | 141               | 23          | 214         | 1.22 [0.63, 2.34]           |
| Subtotal (95% CI) |               |                   |             | 8297        | 1.32 [1.02, 1.70]           |

Total events: 893, Heterogeneity: Tau^2=0.10; Chi^2=41.16, df=14 (P=0.0002); I^2=66%

Test for overall effect: Z=2.15 (P=0.03)

Total (95% CI): 11154, 58866, 100.0%, 2.04 [1.60, 2.61] (P=0.001)

Test for overall effect: Z=4.77 (P<0.00001)

Test for subgroup difference: Chi^2=33.89, df=1 (P<0.00001), I^2=97.0%

**FIGURE 6** Forest plots depict the ORs for comparing COPD between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients.

**DISCUSSION**

The rapid increase in the number of COVID-19 cases and death toll is having devastating social and economic consequences around...
the world. Early identification and timely treatment of severe cases are vitally important in resource-limited countries to save more lives with limited healthcare facilities. This systematic review and meta-analysis of comparative studies suggested that the severity of patients with COVID-19 was significantly associated with pre-existing comorbidities. To the best of our knowledge, this study is the first meta-analysis to compare the comorbidities between severe versus non-severe COVID-19 patients in Asian and non-Asian populations. We found that the incidence of hypertension, diabetes, cardiovascular disease and chronic kidney disease was significantly higher in severe compared to non-severe patients in both Asian and non-Asian group in terms of subgroup analysis.

### FIGURE 7

Forest plots depict the ORs for comparing chronic kidney disease between severe and non-severe cases in SARS-CoV-2 infected Asian versus non-Asian patients.

| Study or Subgroup | Severe Events | Total Events | Non-severe Events | Total Events | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|---------------|--------------|-------------------|--------------|-------------------------------|-------------------------------|
| **2.6.1 Asian studies** | | | | | | |
| Abohmar S | 66 | 352 | 38 | 416 | 4.5% | 2.30 [1.50, 3.52] |
| Alqahtani AM | 1 | 47 | 5 | 411 | 0.9% | 1.77 [0.20, 15.44] |
| Du RH | 1 | 51 | 7 | 58 | 1.0% | 0.15 [0.02, 1.23] |
| Guan WJ | 3 | 173 | 5 | 926 | 1.7% | 3.25 [0.77, 13.73] |
| Guner R | 1 | 50 | 5 | 172 | 0.9% | 0.68 [0.08, 5.97] |
| Guo T | 5 | 52 | 1 | 135 | 0.9% | 14.26 [1.62, 125.18] |
| Khamis F | 1 | 24 | 3 | 39 | 0.8% | 0.52 [0.05, 5.32] |
| Khan A | 2 | 77 | 10 | 571 | 1.6% | 1.50 [0.32, 6.96] |
| Lee JY | 4 | 137 | 1 | 557 | 0.9% | 16.72 [1.85, 150.83] |
| Lee SG | 28 | 927 | 20 | 6412 | 4.0% | 9.95 [5.58, 17.74] |
| Li C | 18 | 476 | 13 | 1592 | 3.5% | 4.77 [2.32, 9.82] |
| Li X | 6 | 289 | 4 | 278 | 2.0% | 1.56 [0.44, 5.60] |
| Omrania AS | 13 | 108 | 21 | 1301 | 3.5% | 8.34 [4.05, 17.18] |
| Shahriariarad R | 0 | 11 | 6 | 102 | 0.6% | 0.65 [0.03, 12.22] |
| Shi S | 5 | 82 | 9 | 334 | 2.4% | 2.34 [0.76, 7.19] |
| Wang D | 2 | 36 | 2 | 102 | 1.1% | 2.94 [0.40, 21.69] |
| Wu J | 2 | 83 | 1 | 197 | 0.8% | 4.64 [0.43, 54.12] |
| Yang L | 2 | 29 | 1 | 171 | 0.8% | 12.50 [1.10, 143.60] |
| Zhang G | 5 | 55 | 1 | 166 | 0.9% | 16.50 [1.88, 144.54] |
| Zhang JJ | 3 | 58 | 2 | 82 | 1.2% | 2.18 [0.35, 13.49] |
| **Subtotal (95% CI)** | 3097 | 14022 | 33.9% | 3.24 [2.01, 5.23] |
| **Total events** | 168 | 155 | | | | |
| **Heterogeneity: Tau² = 0.55; Chi² = 48.92, df = 19 (P = 0.0002); I² = 61%** |
| **Test for overall effect: Z = 4.81 (P < 0.00001)** |

| **2.6.2 Non-Asian studies** | | | | | | |
| Argenziano MG | 27 | 236 | 98 | 614 | 4.4% | 0.68 [0.43, 1.07] |
| Buckner FS | 15 | 51 | 12 | 54 | 3.0% | 1.46 [0.50, 3.52] |
| Cattelan AM | 3 | 69 | 12 | 234 | 2.0% | 0.84 [0.23, 3.07] |
| Filardo TD | 15 | 135 | 21 | 135 | 3.5% | 0.68 [0.33, 1.38] |
| Garibaldi BT | 23 | 171 | 43 | 523 | 4.1% | 1.73 [1.01, 2.97] |
| Giustino G | 49 | 190 | 10 | 115 | 3.5% | 3.65 [1.77, 7.54] |
| Gregoriano C | 10 | 35 | 18 | 64 | 2.9% | 1.02 [0.41, 2.55] |
| Jourdes A | 3 | 50 | 21 | 213 | 2.1% | 0.58 [0.17, 2.04] |
| Kaeuffer C | 49 | 424 | 68 | 621 | 4.6% | 1.06 [0.72, 1.57] |
| Lombardi CM | 76 | 278 | 34 | 336 | 4.4% | 3.34 [2.15, 5.20] |
| Oud L | 34625 | 132197 | 1013 | 4531 | 5.3% | 1.23 [1.15, 1.32] |
| Petrilli CM | 259 | 990 | 321 | 1739 | 5.1% | 1.57 [1.30, 1.89] |
| Popov GT | 5 | 43 | 2 | 95 | 1.4% | 6.12 [1.14, 32.92] |
| Raad M | 197 | 390 | 111 | 630 | 4.9% | 4.77 [3.59, 6.35] |
| Schonfeld D | 349 | 5652 | 1357 | 41703 | 5.2% | 1.96 [1.73, 2.21] |
| Suleyman G | 83 | 141 | 78 | 214 | 4.4% | 2.50 [1.51, 3.86] |
| Turcott JI | 20 | 48 | 7 | 69 | 2.7% | 6.33 [2.40, 16.68] |
| Yazdanpanah Y | 9 | 71 | 7 | 175 | 2.6% | 3.48 [1.24, 9.76] |
| **Subtotal (95% CI)** | 141171 | 52065 | 66.1% | 1.79 [1.39, 2.30] |
| **Total events** | 35817 | 3233 | | | | |
| **Heterogeneity: Tau² = 0.19; Chi² = 172.20, df = 17 (P < 0.00001); I² = 90%** |
| **Test for overall effect: Z = 4.52 (P < 0.00001)** |

**Total (95% CI)** 144268 66087 100.0% 2.23 [1.77, 2.81] 0.01 0.1 1 100 0.01 0.1 1 100

**Favours [Non-severe] Favours [Severe]** 35985 3308 Heterogeneity: Tau² = 0.26; Chi² = 273.27, df = 37 (P < 0.00001); I² = 86% Test for overall effect: Z = 6.81 (P < 0.00001) Test for subgroup differences: Chi² = 4.62, df = 1 (P = 0.03), I² = 78.4%
Our findings are consistent with previous studies that showed a statistically significant association of pre-existing comorbidities with severe COVID-19 cases (Del Sole et al., 2020; Yang, Zheng, et al., 2020; Zhang, Lee, et al., 2020; Zhou, Yang, et al., 2020). Additionally, among Asian studies, there was a statistically significant difference between cancer and COPD incidence between severe and non-severe COVID-19 patients. However, the incidence of cancer and COPD in severe and non-severe non-Asian patients demonstrated no statistically significant difference.

Meta-analysis by Yin et al. (2021) assessed the role of comorbidity in COVID-19 progression in Chinese patients and indicated that chronic kidney disease, cardiovascular disease, cancer, diabetes and hypertension were the strongest risk factor in disease exacerbation. Besides, Yang, Zheng, et al. (2020) showed that the pooled odds ratio of hypertension, respiratory system disease and cardiovascular disease were 2.36, 2.46 and 3.42, respectively, between severe and non-severe patients. Another meta-analysis by Giri et al. (2020) concluded that incidence of hypertension, cardiovascular disease, diabetes and cancer in the severe group was statistically significant higher than non-severe group. However, in their meta-analysis, all included studies were from China. Although we could not find any meta-analysis that compared comorbidities between severe and non-severe COVID-19 patients for the non-Asian studies only; however, the result of individual studies published in non-Asian countries showed that hypertension, cardiovascular disease, diabetes and cancer incidences were higher in severe or ICU groups (Argenziano et al., 2020; Buckner et al., 2020; Cattelan et al., 2020; Ferguson et al., 2020; Filardo et al., 2020; Pellaud et al., 2020; Schönfeld et al., 2021). Our findings are in line with current knowledge that patients with comorbidities are more susceptible to severe infection.

Pre-existing cardiovascular disease and cardiovascular risk factors such as hypertension and diabetes enhance vulnerability to COVID-19 as the SARS-CoV-2 enters lung cells via the ACE2 receptor (Ni et al., 2020). Furthermore, COVID-19 may induce direct myocardial injury by upregulation of angiotensin-converting enzyme (Zheng et al., 2020). Additionally, renin–aldosterone–angiotensin system (RAAS) plays a vital role in the pathogenesis of COVID-19 and Tignanelli et al. (2020) revealed that hypertensive patients have hyperactive RAAS activation through angiotensin-2, which may lead to acute lung injury during SARS-CoV-2 virus infection. Previous studies (Al-Salamah et al., 2021; Zhou et al., 2021) have demonstrated that patients with diabetes were associated with significantly higher risk of suffering from severe COVID-19 confirming that inflammation is important in the pathogenesis of severe COVID-19. Due to weakened immune systems, people with cancer are considered as a highly vulnerable group for COVID-19. This was further supported by study by Liang et al. (2020) as people with cancer were at increased risk of severe clinical events in a nationwide cohort study in China. A recent meta-analysis that evaluated the effects of cancer on patients with COVID-19 also showed that people with cancer were more susceptible to COVID-19 especially for those who had lung cancer than those without lung cancer (Yang, Chai et al., 2021). A meta-analysis that was performed to evaluate the association of chronic kidney disease demonstrated that COVID-19 patients with pre-existing chronic kidney disease had significantly increased risks of progression to a severe condition and even death (Wang, Luo et al., 2021).

Another study that examined the clinical courses of critically ill COVID-19 patients with and without pre-existing chronic kidney disease suggested that underlying kidney disease confers higher risk for individuals with COVID-19 with poorer COVID-19 outcomes (Flythe et al., 2021). Therefore, clinicians should closely monitor CKD patients with suspected COVID-19 to prevent disease progression. People with specific comorbid and underlying conditions are at high risk for COVID-19 severity and mortality. Hence, these population groups should be prioritized for access to COVID-19 vaccination regardless of their geographical location.

There are several limitations to this systematic review and meta-analysis. First, most of the studies included in the meta-analysis were retrospective and conducted in different countries, settings and variation in reporting of medical conditions may be present. Second, high heterogeneity among included studies might be due to the large variation among studies in the sample size. Third, there was heterogeneity in the definition of moderate and severe cases of COVID-19 patients, which might have contributed to the high heterogeneity of the meta-analysis. Fourth, as our topic was related to current pandemic and we already initiated literature searches hence we failed to register in the PROSPERO. However, during systematic processes involved in our literature review we strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines. Despite these limitations, to the best of our knowledge, our study is the first systematic review and meta-analysis that examined comorbidities among severe and non-severe COVID-19 patients by including a large number of high-quality studies from Asian and non-Asian countries with large sample sizes.

5 | CONCLUSION

In conclusion, this systemic review and meta-analysis showed that the incidence of hypertension, diabetes, cardiovascular disease and chronic kidney disease was significantly higher in severe compared to non-severe patients in both Asian and non-Asian population. Despite the continuous efforts to prevent and reduce severity of the disease the COVID-19 pandemic is exacting enormous medical and economic tolls on human life. Timely identification of comorbidities predictive for severe disease and ICU admission, can help frontline health workers such as doctors and nurses to effectively prioritize individual at risk in countries with limited resources. Patients with comorbidities have a tendency to develop severe or critical disease and have a poor disease outcome. More attention should be given to the care of patients with pre-existing comorbidities. More well designed and high-quality randomized-control studies that use standardized patient selection are needed to confirm our findings.
ACKNOWLEDGEMENTS
Not applicable.

CONFLICTS OF INTEREST
The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTIONS
AP, LH, MG and QHZ: conceptualization. AP, LH, MG and CFW: methodology. AP, LH, MG: statistical analysis. AP, LH, MG: data extraction and management. AP, LH, MG and QHZ: writing—original draft preparation. AP, LH, MG, QHZ and CFW: writing—review and editing. QHZ: supervision. All authors contributed to the article and approved the submitted version.

ETHICAL APPROVAL
Ethical review and approval is not required as this is systemic review and meta-analysis.

DATA AVAILABILITY STATEMENT
The data used to support the findings of this study are available from the studies included in this meta-analysis.

ORCID
Mohan Giri https://orcid.org/0000-0001-8588-5482

REFERENCES
Abdohamr, S. I., Abazid, R. M., Aldossari, M. A., Amer, H. A., Badhawi, O. S., Aljunaidi, O. M., Alzarzour, S. H., Saadeddin, H. M., Bhat, F. A., & Elseikh, E. (2020). Clinical characteristics and in-hospital mortality of COVID-19 adult patients in Saudi Arabia. Saudi Medical Journal, 41(11), 1217-1226. https://doi.org/10.15537/smj.2020.11.25495
Alqahtani, A. M., AlMalki, Z. S., Alalweet, R. M., Almazrou, S. H., Alanazi, A. S., Alnazi, M. A., AlShehri, A. A., & AlGhamdi, S. (2020). Assessing the severity of illness in patients with Coronavirus Disease in Saudi Arabia: A retrospective descriptive cross-Sectional Study. Frontiers in Public Health, 8, 593256. https://doi.org/10.3389/fpubh.2020.593256
Al-Salameh, A., Lanoix, J.-P., Bennis, Y., Andrejak, C., Brochet, E., Deschasse, G., Dupont, H., Goeb, V., Jaureguy, M., Lion, S., Maizel, J., Moyet, J., Vaysse, B., Desaillou, R., Ganry, O., Schmit, J.-L., & Lalau, J.-D. (2021). Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes. Diabetes/Metabolism Research and Reviews, 37(3), e3388. https://doi.org/10.1002/dmr.3388
Argenziano, M. G., Bruce, S. L., Slater, C. L., Tiao, J. R., Baldwin, M. R., Barr, R. G., Chang, B. P., Chau, K. H., Choi, J. J., Gavin, N., Goyal, P., Mills, A. M., Patel, A. A., Romney, M.-L., Safford, M. M., Schluger, N. W., Sengupta, S., Sobieszczyk, M. E., Zucker, J. E., ... Chen, R. (2020). Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: Retrospective case series. BMJ, 369, m1996. https://doi.org/10.1136/bmj.m1996 Bastug, A., Bodur, H., Erdogan, S., Gokcinar, D., Kazanciouglu, S., Kosovali, B. D., Ozbay, B. O., Gok, G., Turan, I. O., Yilmaz, G., Goncu, C. C., & Yilmaz, F. M. (2020). Clinical and laboratory features of COVID-19: Predictors of severe prognosis. International Immunopharmacology, 88, 106950. https://doi.org/10.1016/j.intimp.2020.106950 Buckner, F. S., Mc Culloch, D. J., Atiliki, V., Blain, M., McGuffin, S. A., Nalla, A. K., Huang, M.-L., Greninger, A. L., Jerome, K. R., Cohen, S. A., Neme, S., Green, M. L., Chu, H. Y., & Kim, H. N. (2020). Clinical features and outcomes of 105 hospitalized patients with COVID-19 in Seattle, Washington. Clinical Infectious Diseases, 71(16), 2167-2173. https://doi.org/10.1093/cid/ciaa362 Cao, J., Zheng, Y., Luo, Z., Mei, Z., Yao, Y., Liu, Z., Liang, C., Yang, H., Song, Y., Yu, K., Gao, Y., Zhu, C., Huang, Z., Qian, J., & Ge, J. (2020). Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease. Theranostics, 10(21), 9663-9673. https://doi.org/10.7150/thno.47980 Cao, Z., Li, T., Liang, L., Wang, W., Wei, F., Meng, S., Cai, M., Zhang, Y., Xu, H., Zhang, J., & Jin, R. (2020). Clinical characteristics of Coronavirus Disease 2019 patients in Beijing, China. PLoS One, 15(6), e0234764. https://doi.org/10.1371/journal.pone.0234764 Cattelan, A. M., Di Meco, E., Trevenzoli, M., Frater, A., Ferrari, A., Villano, M., Gomiero, F., Carretta, G., & Sassetti, L. (2020). Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: A comparative study. BMC Infectious Diseases, 20(1), 934. https://doi.org/10.1186/s1287 9-020-05647-7 Del Sole, F., Farcomeni, A., Loffredo, L., Carnevale, R., Menichelli, D., Vicario, T., Pignatelli, P., & Pastorì, D. (2020). Features of severe COVID-19: A systematic review and meta-analysis. European Journal of Clinical Investigation, 50(10), e13378. https://doi.org/10.1111/ ejci.13378 Du, R.-H., Liu, L.-M., Yin, W., Wang, W., Guan, L.-L., Yuan, M.-L., Li, Y.-L., Hu, Y., Li, X.-Y., Sun, B., Peng, P., & Shi, H.-Z. (2020). Hospitalization and critical care of 109 decedents with COVID-19 Pneumonia in Wuhan, China. Annals of the American Thoracic Society, 17(7), 839-846. https://doi.org/10.1513/AnnalsATS.202003-225OC Fergusson, J., Rossier, J. I., Quintero, O., Scott, J., Subramanian, A., Gumma, M., Rogers, A., & Kappagoda, S. (2020). Characteristics and outcomes of Coronavirus Disease patients under nonsurge conditions, Northern California, USA, March-April 2020. Emerging Infectious Diseases, 26(8), 1679-1685. https:// doi.org/10.3201/eid2608.201776 Filardo, T. D., Khan, M. R., Krawczyk, N., Galitzer, H., Karmen-Tuohy, S., Coffee, M., Schaye, V. E., Eckhardt, B. J., & Cohen, G. M. (2020). Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). PLoS One, 15(11), e0242760. https://doi.org/10.1371/journ al.pone.0242760 Flythe, J. E., Assimon, M. M., Tugman, M. J., Chang, E. H., Gupta, S., Shah, J., Sosa, M. A., Renaghan, A. D., Melamed, M. L., Wilson, F. P., Neyra, J. A., Rashidi, A., Boyle, S. M., Anand, S., Christov, M., Thomas, L. F., Edmonston, D., & Leaf, E. D. (2021). Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. American Journal of Kidney Diseases, 77(2), 190–203.e1. https://doi.org/10.1053/j.ajkd.2020.09.003 Garibaldi, B. T., Fiksel, J., Muschelli, J., Robinson, M. L., Routhizadeh, M., Perin, J., Schumock, G., Nagy, P., Gray, J. H., Malapati, H., Gbodabi-Krueger, M., Niessen, T. M., Kim, B. S., Hill, P. M., Ahmed, M. S., Dobkin, E. D., Blanding, R., Abele, J., Woods, B., ... Gupta, A. (2021). Patient trajectories among persons hospitalized for COVID-19: A cohort Study. Annals of Internal Medicine, 174(1), 33–41. https://doi.org/10.7326/M20-3905 Giri, M., Puri, A., Wang, T., & Guo, S. (2020). Clinical features, comorbidities, complications and treatment options in severe and non-severe COVID-19 patients: A systemic review and meta-analysis. Nursing Open, 8(3), 1077–1088. https://doi.org/10.1002/nop.2718 Giustino, G., Croft, L. B., Stefanini, G. G., Bragato, R., Silbiger, J. J., Vicenzi, M., Danilov, T., Kukar, N., Shaban, N., Kini, A., Camaj, A., Bienstock, S. W., Rashed, E. R., Rahman, K., Oates, C. P., Buckley, J. E., & Stielf, J. P., (2020). COVID-19: A retrospective analysis of the first 1000 cases in Seattle, Washington. Clinical Infectious Diseases, 71(16), 2167-2173. https://doi.org/10.1093/cid/ciaa362
Limbole, E. B., Ntalaja, J. M., & Kongo, R. M. (2020). Clinical characteristics of COVID-19 patients hospitalized at Clínique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study. PLoS One, 15(12), e0244272. https://doi.org/10.1371/journal.pone.0244272

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097

Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., Xu, Y., Cao, Z., & Gao, Z. (2020). Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care (London, England), 24(1), 422. https://doi.org/10.1186/s13054-020-03120-0

Omran, A. S., Almaslamani, M. A., Daghfal, J., Alattar, R. A., Elgara, M., Almaslamani, M. A., Khashaw, M., Alsharif, G. F., Obaid, E. F., Melebali, H. A., Alamri, D. M., Brini, A. S., Al Jehani, F. H., Almahaimi, W., Ekram, R. A., Alkhamb, K. H., & Alwafi, H. (2020). Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. PLoS One, 15(8), e0237130. https://doi.org/10.1371/journal.pone.0237130

Shahriariad, R., Khodamoradi, Z., Erfani, A., Hosseinpour, H., Ranbar, K., Emami, Y., Mirahmadiadeh, A., Lotfi, M., Shirazi Yeganeh, B., Dorrani Nejad, A., Hemmati, A., Ebrahim, M., & Moghadami, M. (2020). Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. BMC Infectious Diseases, 20(1), 427. https://doi.org/10.1186/s12879-020-05128-x

Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., Gong, W., Liu, X., Liang, J., Zhao, Q., Huang, H., Yang, B., & Huang, C. (2020). Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan. China. JAMA Cardiology, 5(7), 802–810. https://doi.org/10.1001/jamacardio.2020.0950

Slim, K., Nini, E., Forestier, D., Kwiatkowski, F., Panis, Y., & Chipponi, J. (2003). Methodological index for non-randomized studies (minors): Development and validation of a new instrument. ANZ Journal of Surgery, 73(9), 712–716. https://doi.org/10.1016/S0003-6869(03)02748.x

Stefan, G., Mehedinti, A. M., Andreiana, I., Zugravu, A. D., Cinca, S., Busuioc, R., Miler, I., Stancu, S., Petrescu, L., Dimitriu, I., Moldovanu, E., Crasnaru, D. E., Gugonea, G., Georgescu, V., Strambu, V. D., & Capusa, C. (2021). Clinical features and outcome of maintenance hemodialysis patients with COVID-19 from a tertiary nephrology care center in Romania. Renal Failure, 43(1), 49–57. https://doi.org/10.1080/00365513.2020.1846211

Sulejmani, A., Galimberti, E., Giacobone, C., Milano, A., Scopetta, E., Suleyman, G., Fadel, R. A., Malette, K. M., Hammond, C., Abdulla, H., Entz, A., Demertzis, Z., Hanna, Z., Failla, A., Daghe, C., Chaudry, Z., Vahia, A., Abreu Lanfranco, O., Ramesh, M., Zervos, M. J., Alagandang, G., Miller, J. & Brar, I. (2020). Clinical characteristics and morbidity associated with Coronavirus Disease 2019 in a series of patients in a large community healthcare system in South Florida. Journal of Community Health, 46(4), 822–831. https://doi.org/10.1007/s10900-020-00957-y

Schönfeld, D., Arias, S., Bossio, J. C., Fernández, H., Gozal, D., & Pérez-Chada, D. (2021). Clinical presentation and outcomes of the first patients with COVID-19 in Argentina: Results of 207079 cases from a national database. PLoS One, 16(2), e0246793. https://doi.org/10.1371/journal.pone.0246793

Shabrawishi, M., Al-Gethmy, M. M., Naser, A. Y., Ghazawi, M. A., Alsharif, G. F., Obaid, E. F., Melebali, H. A., Alamri, D. M., Brini, A. S., Al Jehani, F. H., Almahaimi, W., Ekram, R. A., Alkhamb, K. H., & Alwafi, H. (2020). Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. PLoS One, 15(8), e0237130. https://doi.org/10.1371/journal.pone.0237130

Tian, S., Hu, N., Lou, J., Kang, X., Xiang, Z., Chen, H., Wang, D., Liu, N., Liu, D., Chen, G., Zhang, Y., Li, D., Li, J., Lian, H., Niu, S., Zhang, L., & Zhang, J. (2020). Characteristics of COVID-19 infection in Beijing. The Journal of Infection, 80(4), 401–406. https://doi.org/10.1016/j.jinf.2020.02.018

Tigianelli, C. J., Ingraham, N. E., Sparks, M. A., Reikoff, R., Bezdek, T., Benson, B., Schacker, T., Chipman, J. G., & Puskarich, M. A. (2020). Antihypertensive drugs and risk of COVID-19? The Lancet Respiratory Medicine, 8(5), e30–e31. https://doi.org/10.1016/S2213-2600(20)30153-3
